Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Macimorelin diagnostic study for pediatric suspected growth hormone deficiency
2018-001989-42Phase 3Completed
- Sponsor
- COSCIENS Biopharma Inc.
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of macimorelin in growth hormone deficiency (GHD), sponsored by COSCIENS Biopharma Inc. Primary endpoint: ROC AUC for macimorelin GH stimulation test. Started May 2021; status: completed.
02
Drugs
macimorelin
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on 2018-001989-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001989-42.